Tanvex BioPharmaTPE:6541 +2.10%57 Days Payable is 15.75 as of Dec. 2025, which is 65% below its 10-year median of 44.66. GuruFocus rates TPE:6541 with a GF Score™ of 57/100 and a GF Value™ of NT$254.61 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, Tanvex BioPharma ranks worse than 90.17% on this metric.
The historical rank and industry rank for Tanvex BioPharma's Days Payable or its related term are showing as below:
TPE:6541'
s Days Payable Range Over the Past 10 Years
Min: 18.34 Med: 44.66 Max: 44.66
Current: 18.34
During the past 13 years, Tanvex BioPharma's highest Days Payable was 44.66. The lowest was 18.34. And the median was 44.66.
TPE:6541's Days Payable is ranked worse than 90.17% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs TPE:6541: 18.34
Tanvex BioPharma's Days Payable
increased
from Dec. 2024 (0.00) to Dec. 2025 (15.75).
It may suggest that Tanvex BioPharmadelayed paying its suppliers.
Tanvex BioPharma Days Payable Related Terms
Tanvex BioPharma Days Payable Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6541 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Tanvex BioPharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Tanvex BioPharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma (TPE:6541) has a Days Payable of 15.75 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tanvex BioPharma and its competitors. This is 65% below median its historical median of 44.66. Over the past decade, Tanvex BioPharma's Days Payable has ranged from 18.34 to 44.66. According to the industry distribution chart, Tanvex BioPharma ranks #633 out of 702 companies in the Biotechnology industry, placing it in the top 90.2%.
Is Tanvex BioPharma's Days Payable too high?
Tanvex BioPharma's current Days Payable of 15.75 is 65% below median its 10-year median of 44.66. Over the past 10 years, this metric has ranged from a low of 18.34 to a high of 44.66. The Biotechnology industry median Days Payable is 113.10. Tanvex BioPharma's value of 15.75 is 86.1% below this industry median. Based on the distribution chart, Tanvex BioPharma ranks #633 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #633 out of 702 companies for Days Payable. This places Tanvex BioPharma in the lower half of its industry. The industry median Days Payable is 113.10. Tanvex BioPharma's value of 15.75 is 86.1% below this benchmark. Historically, Tanvex BioPharma's own Days Payable has ranged from 18.34 to 44.66 over the past decade. While the company's 10-year median is 44.66 vs. the industry median of 113.10, Tanvex BioPharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tanvex BioPharma's current Days Payable of 15.75 is 86.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tanvex BioPharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tanvex BioPharma's current Days Payable is 15.75, which is 65% below median its own 10-year median of 44.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current Days Payable is 15.75, which is 65% below median its 10-year median of 44.66 and 86.1% below the Biotechnology industry median of 113.10. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Days Payable is 15.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?
Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued.
The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61.
GuruFocus considers Tanvex BioPharma to be Possible Value Trap.
Key valuation signals for TPE:6541:
Days Payable: 15.75 (65% below median its 10-year median of 44.66)
GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
Industry Position: 86.1% below the Biotechnology median (#633 of 702)
No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score
Get the complete analysis for TPE:6541
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
